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ABSTRACT  
Background: Peyronie’s disease (PD) is a chronic fibrotic disease of the penis affecting a significant 
number of men worldwide without effective medical treatments. Myofibroblasts are pivotal in the 
pathogenesis of PD. Adenosine and adenosine receptors have been suggested to be involved in the 
pathophysiology of fibrosis. 
Aim: To understand the role of adenosine receptors in myofibroblast transformation in PD.  
Methods: Fibroblasts were isolated from the non-PD tunica albuginea (TA) tissue and PD plaque tissue 
and were transformed into myofibroblasts using transforming growth factor β1 (TGF-β1). Quantification of 
alpha smooth muscle actin (α-SMA) and adenosine receptors (ADORA1, ADORA2A, ADORA2B and 
ADORA3) was performed using immunocytochemistry (ICC), In-Cell ELISA (ICE) and real-time RT-PCR 
(RT-qPCR). The effect of various adenosine receptor agonists or antagonists on TGF-β1-induced 
myofibroblast transformation was measured using ICE.  
Outcomes: Expression of adenosine receptors in myofibroblasts obtained from human TA and the effect 
of adenosine receptor ligands on myofibroblast transformation. 
Results: ICC, ICE and RT-qPCR experiments showed that the protein and mRNA levels of α-SMA in non-
PD TA cells and PD plaque-derived cells were significantly higher in cells exposed to TGF-β1 than those 
not treated with TGF-β1. Two of four adenosine receptors (ADORA1 and ADORA2B) were found to be 
expressed in both cell populations. Among various adenosine receptor agonists/antagonist investigated, 
only ADORA2B agonist, BAY60-6583, significantly inhibited myofibroblast transformation in a 
concentration-dependent manner when applied simultaneously with TGF-β1 (IC50=30 µM). 
Clinical Translation: ADORA2B antagonists may be clinically efficacious in early stage PD. 
Strengths & Limitations: The strength of this study is the use of primary fibroblasts from human TA. 
Limitation of the study is the high concentrations of the ligands used. 
Conclusions: The effect of an ADORA2B agonist on TGF-β1-induced myofibroblast transformation shows 
a novel potential therapeutic target for PD if applied during early, non-stable phase of PD.  
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INTRODUCTION 
Fibrosis can be described as excessive development of fibrous connective tissue, which can occur in 
various tissue types and organs (e.g. kidney, lung, skin and liver). At a cellular level tissue resident 
quiescent fibroblasts and other cells such as endothelial, epithelial cells, and fibrocytes can differentiate 
into myofibroblasts which have a crucial role in fibrosis characterised by increased proliferation, increased 
extracellular matrix (ECM) protein production and contraction1,2. Moreover, their persistence (i.e. failure to 
undergo apoptosis) and proliferation has been suggested to be one of the hallmarks of chronic fibrosis3,4. 
Peyronie’s disease (PD) is a fibrotic disorder characterised by the formation of plaques within the tunica 
albuginea (TA) of the penis5. Although its aetiology is still poorly understood, microvascular trauma has 
been postulated as the initiating factor6. This fibrotic disorder is also characterised by the expression of 
several cytokines and growth factors, fibrin deposition and myofibroblast differentiation7. In PD, the 
myofibroblast activity is increased, resulting in increased ECM protein production and eventual plaque 
formation 7–11 suggesting a pivotal role for myofibroblasts in the pathophysiology of PD.  
Inhibition of differentiation of quiescent fibroblasts to pro-fibrotic myofibroblasts has been suggested as a 
therapeutic approach for fibrosis4. Accordingly, we have been investigating potential molecular targets that 
may be involved in myofibroblast differentiation and small molecule compounds that may inhibit this 
process.  
One of such target that is suggested in pathophysiology of fibrosis is adenosine and its receptors. 
Adenosine is a ubiquitous purine nucleoside released from cells and tissues under conditions of stress or 
injury and is generated intracellularly and extracellularly from adenine nucleotides which are then 
dephosphorylated to adenosine. CD39 and CD73 are two cell surface molecules responsible for catalysing 
the dephosphorylation of adenine nucleotides to adenosine in the extracellular space12,13. Adenosine 
regulates its effects on tissue regeneration and repair via the interaction with a family of G-protein coupled 
receptors: adenosine receptor A1 (ADORA1), adenosine receptor A2A (ADORA2A), adenosine receptor 
A2B (ADORA2B) and adenosine receptor A3 (ADORA3)14.  
Several studies have shown that adenosine receptors play different roles in acute and chronic injuries. In 
acute tissue injury, adenosine has been shown to be beneficial, as it is responsible for tissue protection and 
anti-inflammatory responses13 (e.g. promotion of barrier function and wound healing) in several organs, 
including kidney15, lung16, heart17 and liver18. In contrast to acute states, increased levels of adenosine have 
been associated with the progression of chronic tissue injuries. In these settings, adenosine has been 
suggested to promote fibrosis in several organs, such as the heart19, skin20, liver21, lung22, penis23 and 
kidney24. The adenosine receptors play different roles in the pathogenesis of fibrosis depending on the 
tissue subtype involved; however, the effects of adenosine are mainly regulated by ADORA2A and 
ADORA2B16. The characterisation of these receptors has been investigated in other fibrotic disorders; 
however, no characterisation of these receptors has been carried out in Peyronie’s disease. By 
understanding how adenosine receptors may regulate the response to injury in this specific tissue and by 
looking at the myofibroblast transformation process, it may provide new insights into the pathophysiology 
of fibrosis in general and in PD. Furthermore, by targeting the respective pathway and by investigating the 
effect of selective agonist and antagonist compounds, it may enable avenues to identify potential targets 
for the treatment of PD and other fibrotic disorders and enhance the resolution of the injury or halt the 
progression of fibrosis in PD.  
The aim of this study was to understand the involvement of adenosine receptors in the myofibroblast 
differentiation in PD by characterising the myofibroblast transformation process in tunica albuginea-derived 
fibroblasts to identify potential, novel targets for anti-fibrotic therapies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
Sample acquisition  
Tunica albuginea (TA) tissue samples were acquired from patients undergoing corrective surgery for PD 
(to be referred to as PD plaque tissue) or invasive penile cancer (to be referred to as non-PD TA tissue) at 
University College London Hospital (UCLH), UK. Patients aged between 18 and 75, listed for surgical 
treatment of PD or penile cancer at UCLH, able to understand the patient information sheet and to give 
consent were included in this study. Ethical approval was obtained by local independent research ethics 
committees (East of England Essex [12-EE-0170] and North of Scotland [15-NS-0051]).  
The non-PD TA tissue was obtained from penis of patients with penile cancer (N=3; average age= 72±10). 
The TA tissue was removed from the proximal side away from the tumour and the tumour had negative 
margins on histology examination.   
The PD TA tissue was obtained from penis of patients with chronic PD (N=3; average age= 61±6). The 
tissue used in this group was the plaque tissue that was surgically removed and would have otherwise been 
discarded. 
Isolation of fibroblasts from TA tissue 
Tissue samples were dissected into small pieces, submerged in culture media in 6 well plates and incubated 
at 37°C, 5% CO2 in a humidified atmosphere for 5-7 days. This method is known as “explant technique” by 
which pure fibroblast cultures can be obtained25. Tissues were removed from the 6 well plates, once cells 
were observed growing out of the tissue. Cells were then washed three times with PBS and fresh, warm 
medium was added to each well. Cells were incubated at 37°C until they reached 50-70% confluence, after 
which old medium was removed and cells were washed with PBS. Cells were detached with 0.25% 
trypsin/EDTA (TE; GIBCO, Invitrogen, UK) and neutralised with culture media. The cell suspension was 
transferred to T75 flasks (NUNC, Thermo Scientific, UK) and the cells were propagated and maintained up 
to passage 10.  
Real-time RT-PCR (RT-qPCR) 
Cells were seeded onto 6 well plates (Nunc, Fisher Scientific, UK) at 1.0 x 105 cells/well and incubated in 
DMEM-F12 medium (GIBCO, Invitrogen, UK) supplemented with 10% FCS (Fisher Scientific, UK) and 1% 
penicillin-streptomycin (GIBCO, Invitrogen, UK). After overnight incubation, fibroblasts were incubated with 
or without TGF-β1 (Sigma-Aldrich, UK; 10 ng/ml) for 72 hours. Total RNA was extracted from cells using 
the RNeasy Mini Kit (QIAGEN, UK) according to the manufacturer’s instructions and a DNAse digestion 
step was included to eliminate genomic DNA contamination (RNAse-free DNAse set, QIAGEN, UK). cDNA 
was generated from 500 ng of RNA by reverse transcription using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, UK), according to manufacturer’s instructions. Real-time PCR was 
performed using the QuantiTect® SYBR® Green PCR kit (QIAGEN, UK), following the manufacturer’s 
instructions and the CFX Connect Real-time PCR detection system (Bio-Rad, UK). Gene-specific primer 
pairs for genes encoding α-SMA (NM_001613, 98 bp) were purchased from Sigma-Aldrich, UK and 
ADORA1 (NM_000674.2, 96 bp), ADORA2A (NM_000675.5, 93 bp), ADORA2B (NM_000676.2, 117 bp) 
and ADORA3 (NM_000677.3, 139 bp) were purchased from Primerdesign, UK. The primers for EIF4A2 
(NM_001967, 87 bp), TOP1 (NM_003286, 89 bp), vimentin (NM_003380) and desmin (NM_001927) were 
purchased from QIAGEN, UK. PCR reactions were carried out by performing an initial activation step for 
15 minutes at 95°C, followed by 40 cycles at 94°C for 15 seconds, 55°C for 30 seconds and 72°C for 30 
seconds. All samples and negative controls (no template control and no reverse transcriptase enzyme 
control) were run in triplicate and in addition, a melting curve was generated at the end of the PCR cycle to 
ensure amplification of a single product. Relative mRNA levels were calculated using the 2-ΔΔCt method26 
and obtained as fold-change of the target gene in the test samples relative to the calibrator sample and 
normalised to the expression of the reference genes (EIF4A2 and TOP1).  
Immunocytochemistry (ICC) 
Fibroblasts obtained from tunica albuginea tissue samples were seeded onto coverslips (Fisher Scientific, 
UK) at 2.5 x 105 cells/well and were incubated with or without TGF-β1 (10 ng/ml) for 72 hours. After 
incubation, cells were washed with PBS (GIBCO, Invitrogen, UK) and fixed in ice-cold methanol (-25°C; 
Fisher Scientific, UK) for 10 seconds. Cells were then washed with PBS and 10% donkey serum (EMD-
Millipore, UK) in PBS was added for 1 hour at room temperature. Blocking solution was then replaced by 
primary antibody solution (1:1,000 dilution of mouse monoclonal anti-α-SMA antibody, Sigma-Aldrich, UK; 
1:1,000 dilution of mouse monoclonal vimentin, Abcam, UK;  or 1:100 mouse monoclonal desmin, Abcam, 
UK) diluted in PBS for 2 hours at room temperature in a humidified chamber. Cells were washed three 
times with PBS, after which, they were incubated with the donkey anti-mouse secondary antibody 
conjugated with fluorescein dye (Millipore, UK) at 1:250 dilution in PBS for 2 hours at room temperature in 
a humidified chamber in the dark. After the incubation period, the secondary antibody solution was washed 
three times with PBS and the coverslips were mounted in a glass microscope slide with cells facing down 
with VECTASHIELD® mounting medium with propidium iodide (PI; Vector Laboratories, UK). Cells were 
observed and images were captured using the Zeiss confocal microscope (LSM 510; Carl Zeiss, UK). The 
fluorescence images were taken in at least three random areas in each coverslip from each cell line 
acquired from three different patients (per group) (PD and non-PD). The number of α-SMA-positive cells 
was determined by counting the number of α-SMA-positive cells in three random fields per coverslip and 
the total number of cells was also determined by counting the number of nuclei stained.  
In-Cell ELISA (ICE) 
The expression of α-SMA protein was quantified in 96 well plates using a technique called “In-Cell ELISA” 
(ICE) which involves fixation of the cells on the plate surface, permeabilisation of the cells, staining of the 
proteins with an antibody-ligated with infrared dyes and visualising the infrared-red dyes using an infra-red 
imaging system27. Cells were seeded onto 96 well optical flat bottom black microplates (Nunc, Fisher 
Scientific, UK) at 5.0 x 103 cells /well and left overnight at 37°C, 5% CO2 in a humidified incubator. Media 
was replaced with fresh media with and without agonists and antagonists of adenosine receptors (all 
purchased from TOCRIS, UK) in co-incubation with or without TGF-β1 (5 ng/ml) for 72 hours. N6-
Cyclopentyladenosine (CPA) and BAY 60-6583 were used as ADORA1 and ADORA2B agonists, 
respectively. SLV 320 and MRS 1754 were used as ADORA1 and ADORA2B antagonists, respectively. 
The compounds were dissolved in 100% DMSO to 100 mM stock concentration and further diluted to 100 
μM final assay concentration. After incubation, media was removed, and cells were fixed with 4% 
paraformaldehyde for 20 minutes at room temperature. Fixing solution was then removed and cells were 
washed three times with 0.1% Triton X-100 in PBS. A 5% donkey serum plus 0.1% Triton X-100 in PBS 
solution was incubated with cells for blocking and permeabilisation for 90 minutes at room temperature. 
After removing the buffer, a primary antibody solution diluted in PBS (1:3,000 dilution of mouse monoclonal 
anti-α-SMA antibody, 1:500 dilution of rabbit monoclonal anti-adenosine A1 receptor or 1:500 dilution of 
rabbit polyclonal anti-adenosine A2B receptor) was added and incubated for 2 hours at room temperature. 
Cells were then washed with 0.1% Tween 20 in PBS three times and a solution containing both the 
secondary antibody (donkey anti-mouse or donkey anti-rabbit at 1:500 which emits at 800 nm; IRdye 
800CW; Li-Cor, UK) and a nuclear counterstain at 1:1,000 that emits at 700 nm (DRAQ5, Biostatus, UK) 
diluted in PBS was incubated for 1 hour at room temperature in the dark. Cells were washed three times 
with 0.1% Tween 20 in PBS and the plate was scanned using an infrared imaging system (Odyssey® CLx 
imager, Li-Cor, UK) at both 700 nm and 800 nm wavelengths.  
Statistical analysis 
Data analyses and graphs were plotted using Microsoft® Excel 2013 and presented as mean ± standard 
error of the mean (SEM) since the data was normally distributed according to Shapiro-Wilks test. Statistical 
differences were determined by Student’s t-test for unpaired means (two-sided) with a P value less than 
0.05 considered statistically significant. All experiments were carried out in triplicate using samples from at 
least 3 patients (N=3).   
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Characterisation of cells isolated from non-PD TA tissue and PD plaque tissue 
In order to ascertain that the cells we have isolated from human TA were fibroblasts, we investigated the 
expression of vimentin and desmin since fibroblasts are known to be vimentin-positive and desmin-
negative28. Vimentin was expressed at both protein and mRNA levels in cells obtained from PD plaque 
tissue and non-PD TA tissues. Treatment of the cells with TGF- β1 did not alter the expression of vimentin 
(Figure 1).   
The cells established from non-PD TA tissue and PD plaque tissue were desmin-negative; this was not 
affected by TGF-β1 treatment (Figure 1).  These results confirm that the cells isolated from TA were indeed 
fibroblasts. 
 
Cells derived from non-PD TA tissue and PD plaque tissue express α-SMA   
Myofibroblasts are known to be vimentin-positive, desmin-negative and α-SMA-positive29. The expression 
of α-SMA was investigated in cells isolated from non-PD TA tissue and PD plaque tissue. The mRNA levels 
of α-SMA significantly increased in both cell populations when exposed to TGF-β1 for 72 hours (Figure 2-
E). In addition, α-SMA positive cells were observed in both cell populations in the presence of TGF-β1 
(Figure 2-C and 2-D); whereas, in the absence of TGF-β1, the presence of α-SMA positive cells was rare 
or non-existent in cells established from non-PD TA tissue and PD plaque tissue (Figure 2-A and 2-B). The 
number of α-SMA positive cells in each cell population exposed to TGF-β1 was significantly higher 
compared to untreated cells (Figure 2-F). In order to quantify the protein levels in an objective and higher 
throughput manner, the ICE method was used to test the effect of TGF-β1 on non-PD TA cells and PD 
plaque-derived cells. Similar to the immunocytochemistry results, treatment with TGF-β1 elicited a 
significant increase in expression of α-SMA protein in cells obtained from either non-PD TA or PD plaque 
tissues (Figure 3).  
 
Expression of adenosine receptors in non-PD TA cells and PD plaque-derived cells  
The expression of four adenosine receptors (ADORA1, ADORA2A, ADORA2B and ADORA3) was 
investigated in cells derived from non-PD TA tissue and PD plaque tissue. Both cell populations expressed 
low levels of ADORA2A and ADORA3 (Figure 4); whereas, ADORA2B was expressed in both cell groups 
isolated from healthy and fibrotic tissues and ADORA1 was expressed in cells derived from PD plaque 
tissue. ADORA1 and ADORA2B were significantly higher in cells established from PD plaque tissue than 
from non-PD TA tissue (Figure 4).   
 
Effect of TGF-β1 in ADORA1 and ADORA2B in cells derived from non-PD TA tissue and PD plaque 
tissue 
The transcriptional levels of ADORA1 were significantly reduced in cells treated with TGF-β1 compared to 
untreated cells that were derived from non-PD TA tissue and PD plaque tissue. However, no statistically 
significant difference was observed between non-PD TA cells and PD plaque-derived cells (Figure 5-A). 
Contrary to mRNA levels, the protein levels of ADORA1 were significantly increased when exposed to TGF-
β1 in cells isolated from non-PD TA tissue and PD plaque tissue (Figure 5-B).  
The mRNA levels of ADORA2B were significantly decreased in cells exposed to TGF-β1 compared to cells 
not exposed to TGF-β1 (Figure 6-A). Although, no statistically significant difference was observed in the 
protein levels of ADORA2B when treated with TGF-β1, significance was achieved between non-PD TA cells 
and PD plaque-derived cells (Figure 6-B).  
 
Effect of ADORA1 and ADORA2B agonist and antagonist on TGF-β1-induced myofibroblast 
transformation 
To further investigate the change of ADORA1 and ADORA2B expression and their ability to inhibit 
myofibroblast transformation, agonists and antagonists were used. N6-Cyclopentyladenosine (CPA) and 
BAY 60-6583 were used as ADORA1 and ADORA2B agonists, respectively. On the other hand, SLV 320 
and MRS 1754 were used as ADORA1 and ADORA2B antagonists, respectively.  
ADORA1 agonist (CPA) showed inhibition of TGF-β1-induced myofibroblast transformation only at 100 µM 
in either cell populations. At the same high concentration, the cell viability was also reduced (Figure 7-A). 
ADORA2B agonist (BAY60-6583) significantly inhibited TGF-β1-induced myofibroblast transformation in a 
concentration dependent manner in both non-PD TA cells and PD plaque-derived cells (IC50 = 30 µM) 
(Figure 7-B, 7-E). The compound did not affect cell viability at any concentration tested in TGF-β1-induced 
myofibroblasts (Figure 7-B) or non-stimulated fibroblasts (Supplementary Figure 1).  
ADORA1 antagonist, SLV 320, inhibited TGF-β1-induced myofibroblast transformation only at 100 µM; 
without affecting the cell viability (Figure 7-C). The ADORA2B antagonist, MRS 1754, also failed to inhibit 
TGF-β1-induced myofibroblast transformation in either cell population significantly; the inhibition that was 
observed at only high concentrations was due to decreased cell viability (Figure 7-D).  
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
Although adenosine and its receptors have been studied in other fibrotic diseases, there is a lack of studies 
reporting the characterisation and effects of adenosine receptors in PD. Therefore, the aim of this study 
was to investigate the role of adenosine receptors in myofibroblast transformation in PD. 
First, the cells isolated from non-PD TA tissue and PD plaque tissue were characterised. The results 
showed that both cell groups were positive for vimentin and negative for desmin suggesting that these cells 
were fibroblasts. It was also observed that treatment with TGF-β1 did not alter the expression of these 
specific markers, but significantly increased the expression of α-SMA confirming myofibroblast phenotype29.  
Myofibroblasts have a crucial role in pathophysiology of fibrosis, as these cells are not only responsible for 
contraction but also for production of several cytokines and abundant ECM proteins. Myofibroblast 
transformation is well established in the literature as being an important contributor in the pathophysiology 
of several fibrotic disorders including PD. A key feature of myofibroblasts is their α-SMA expression, which 
can be targeted to investigate the myofibroblast differentiation. Both mRNA and protein levels of α-SMA 
were assessed by exposing cells derived from non-PD TA tissue and PD plaque tissue to TGF-β1. In both 
cell groups, a significant increase of α-SMA mRNA levels was observed when treated with TGF-β1. The 
effect of TGF-β1 on mRNA levels was mirrored by α-SMA protein expression, that is, both cell populations 
showed an increase in α-SMA positive cells in the presence of TGF-β1. These results are supported by 
previously published reports that have shown that both α-SMA mRNA and protein levels increase in the 
presence of TGF-β1 in fibroblasts obtained from PD tissue 10,11.  
Interestingly, α-SMA-positive cell numbers and α-SMA mRNA and protein levels in unstimulated cells 
obtained from PD tissue were similar to those from TA tissue suggesting that basal myofibroblast numbers 
were similar in cultures derived from the two tissue types. Although we did not aim to investigate specifically 
whether PD tissue would yield more myofibroblasts than TA tissue, this was a surprising and unexpected 
finding. We believe that this could be as a result of the choice of method we employed to isolate cells from 
the tissue samples. During the explantation of the tissue and subsequent cell passaging, more fibroblasts 
than myofibroblasts might have migrated from the tissue or myofibroblasts might have reverted in their 
phenotype during cell passaging. Another possibility is that the PD cells could have already been exposed 
to TGF-β1 in the tissue during the formation of the plaque; they may have developed resistance to TGF-β1 
hence their lower responsiveness to TGF-β1 than the TA cells. Nevertheless, our results confirmed that 
both tissue types yielded sufficient number of fibroblasts which can be transformed to myofibroblasts using 
TGF-β1 and can be further utilised in myofibroblast transformation assay. 
Adenosine receptors have been associated with the progression of chronic tissue injuries when the levels 
of adenosine are increased, suggesting that adenosine may promote fibrosis. To the best of the author’s 
knowledge, this is the first time that the expression of adenosine receptors has been investigated in cells 
derived from non-PD TA tissue and PD plaque tissue. In order to demonstrate the involvement of adenosine 
receptors in myofibroblast transformation in PD, the expression of these receptors was investigated in cells 
isolated from non-PD TA tissue and PD plaque tissue. Among the four receptors, the expression of 
ADORA1 and ADORA2B was significantly higher in PD plaque-derived cells than in non-PD TA cells; 
however, this increase was dramatically higher in ADORA1 transcripts levels. The expression of ADORA2A 
and ADORA3 were below the detection limits, therefore these two receptors were not studied further. Zhong 
et al. (2005)30 found that primary human lung fibroblasts expressed high mRNA levels of ADORA2B and 
the expression of this receptor at protein levels was confirmed by immunofluorescence. These authors also 
showed that the activation of the ADORA2B by adenosine promoted myofibroblast transformation. In our 
study, the effect of TGF-β1 on mRNA levels of both adenosine receptors was also assessed, leading to a 
significant decrease of ADORA1 and ADORA2B mRNA levels in both cell groups. Even though the mRNA 
levels were significantly decreased, it may not represent a biological change in the transcript levels, as 
according to MIQE guidelines, to show biological changes a 2-fold (recommended cut-off value) increase 
or decrease should be observed31. The protein levels of ADORA1 and ADORA2B in both cell populations 
was assessed using the ICE assay, showing that a significant increase of ADORA1 was observed in cells 
treated with TGF-β1; however, no difference was observed between non-PD TA cells and PD plaque-
derived cells.  
In addition, Wen et al. (2010)23 showed that primary corpus cavernosal fibroblasts from mice expressed 
ADORA2B, which was suggested to be responsible for adenosine-mediated penile fibrosis. Furthermore, 
two other studies have also shown that deaminase-deficient mice had an increment of adenosine levels 
and ADORA2B activation in the penis, suggesting an essential mechanism for the progression of priapism 
in these mice23,32.  
Receptor expression results therefore suggest that ADORA1 and ADORA2B were expressed in both 
fibroblasts and myofibroblasts derived from TA. It would be worth investigating in the future how these two 
receptors and their downstream pathways may interact in physiological and pathological conditions.   
The role of ADORA1 and ADORA2B was assessed in TGF-β1-induced myofibroblast transformation using 
ADORA1 and ADORA2B agonists and antagonists. CPA and BAY 60-6583 were utilised as ADORA1 and 
ADORA2B agonists, respectively while SLV 320 and MRS 1754 were used as ADORA1 and ADORA2B 
antagonists, respectively. ADORA1 agonist, CPA showed an inhibitory effect on TGF-β1-induced 
myofibroblast transformation only at high concentrations while affecting the cell viability; therefore, we 
conclude that the inhibitory effect is most probably due to cytotoxicity at the high concentrations. ADORA2B 
agonist BAY60-6583 significantly inhibited the transformation in a concentration-dependent manner with 
an IC50 value of 30 µM and had no cytotoxicity either on fibroblasts or myofibroblasts. No inhibition of TGF-
β1-induced myofibroblast transformation was observed with the ADORA1 antagonist (SLV320) and 
ADORA2B antagonist (MRS1754). We are particularly surprised to see no effect by ADORA2B antagonist 
since we would have expected inhibition of myofibroblast transformation with this compound. However, we 
have observed an inhibition by ADORA2B agonist suggesting that endogenous adenosine may have anti-
fibrotic effect under these conditions which obviously warrants further research. 
We conclude that among the four agonists/antagonists tested, ADORA2B agonist BAY60-6583 has proven 
to be the most successful one and further suggest that ADORA2B agonism may be potential therapeutic 
approach for PD. This is further supported by our finding of ADORA2B expression in cells derived from 
human TA with or without PD. It would be worthwhile testing this compound in animal models of Peyronie’s 
disease. 
To our knowledge, BAY60-6583 has not been progressed to clinical development and remains to be the 
only ADORA2B agonist that has been developed33,34. Further development of similar compounds would be 
beneficial in future fibrosis research. 
One of the limitations of our study is being limited to in vitro findings. Although we have used primary 
fibroblasts isolated from fresh human tissue, there is always the risk of our findings not being able to be 
translated to in vivo. Similarly, the IC50 of BAY60-6583 is relatively high; it is unlikely that such a 
concentration can be reached at tissue level in an in vivo situation. Further work would be required to 
understand the pharmacology of ADORA2B agonists in PD. Another limitation is the choice of non-PD TA 
tissue being obtained from patients with penile cancer. Although we made sure that the tissue obtained 
was away from the tumour and the tumour margins were negative in histology examination, we cannot 
exclude the possibility of cancer genetics influencing the fibroblast phenotype.  
 
CONCLUSIONS 
Cell culture models from both non-PD TA tissue and PD plaque tissue were successfully established, with 
confirmed fibroblast identity and differences regarding TGF-β1-induced myofibroblast transformation, 
mainly increased α-SMA mRNA and protein levels in cells isolated from PD plaque tissue.  
The expression of two adenosine receptors (ADORA1 and ADORA2B) was demonstrated in both cell 
groups in which the ADORA2B agonist BAY 60-6583 significantly inhibited TGF-β1-induced myofibroblast 
transformation in the two cell types investigated.  
Inhibition of differentiation of quiescent fibroblasts to pro-fibrotic myofibroblasts has been suggested as a 
therapeutic approach for fibrosis4. The effect of BAY 60-6583 on TGF-β1-induced myofibroblast 
transformation may suggest a novel potential therapeutic target for PD if applied during early, non-stable 
phase of PD and in other fibroproliferative diseases, although we did not test the compounds on cells 
derived from the acute phase of PD. We suggest that such compounds may be useful in early stages of the 
disease to prevent formation of the plaque. 
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FIGURE LEGENDS 
Figure 1: Vimentin and desmin quantification in cells derived from patients with or without 
Peyronie’s disease. Fibroblasts were exposed to TGF-β1 (10 ng/ml) for 72 hours. A, B, C&D: 
Representative images of (A) vimentin stained non-PD TA-derived cells exposed to control conditions; (B) 
desmin stained non-PD TA-derived cells exposed to control conditions; (C) vimentin stained non-PD TA-
derived cells exposed to TGF-β1; (D) desmin stained non-PD TA-derived cells exposed to TGF-β1. Images 
were captured at 200x magnification. Scale bars represent 50 μm. (E) Quantification of vimentin/desmin 
expression non-PD TA-derived cells using ICE. (F) Quantification of vimentin/desmin expression PD TA-
derived cells using ICE. Data points were plotted as mean ± SEM, N=3 patients for each group. (G) 
Representative image for desmin staining of rhabdomyosarcoma cell line RD. (H) Quantification of vimentin 
mRNA expression of non-PD and PD TA-derived cells using qPCR. (I) Quantification of desmin mRNA 
expression of non-PD and PD TA-derived cells using qPCR. Fibroblasts were exposed to TGF-β1 (10 
ng/ml) for 72 hours before RNA isolation. Data points were plotted as mean ± SEM, N=3 patients for each 
group. n.d.=not detectable. 
Figure 1: Expression of α-SMA in cells established from non-PD TA tissue and PD plaque tissue. 
(A) Representative illustrations of α-SMA staining in untreated non-PD TA cells, (B) Representative 
illustrations of α-SMA staining in untreated PD plaque-derived cells, (C) Representative illustrations of α-
SMA staining in non-PD TA cells treated with TGF-β1, (D) Representative illustrations of α-SMA staining in 
PD plaque-derived cells treated with TGF-β1. The nucleus of the cells was stained with PI, a red nuclear 
counterstain, whereas the α-SMA positive cells were stained in green, which is conferred by the FITC 
conjugated secondary antibody. Confocal microscope at 200x magnification. Bar in the corner of each 
image represents 50 µm. (E) α-SMA mRNA levels in cells derived from non-PD TA tissue and PD plaque 
tissue exposed to 10 ng/ml of TGF-β1 for 72 hours. (F) Ratio of α-SMA positive cells in cells derived from 
non-PD TA tissue and PD plaque tissue exposed to TGF-β1 at 10 ng/ml for 72 hours, after which, the 
number of myofibroblasts was calculated by counting the number of α-SMA positive cells in each field and 
then divided by the number of total cells. Data points were plotted as mean ± SEM, N=3. Legend: * indicates 
P<0.05 tested by Student’s t-test vs untreated cells.  
 
Figure 2: α-SMA protein levels in cells derived from non-PD TA tissue and PD plaque tissue. In-Cell 
ELISA was performed to assess the α-SMA protein levels in fibroblasts exposed to TGF-β1 at 10 ng/ml for 
72 hours. Data points were plotted as mean ± SEM, N=3. Legend: * indicates P<0.05 tested by Student’s 
t-test vs untreated cells. 
 
Figure 3: Adenosine receptors mRNA levels in cells derived from non-PD TA tissue and PD plaque 
tissue. The expression of adenosine receptors was determined using the 2ΔCq method, where the result 
obtained corresponds to the fold change of each adenosine receptor relative to the expression of reference 
genes (EIF4A2 and TOP1). Each sample was run in triplicate. Data points were plotted as mean ± SEM, 
N=3. Legend: * indicates P<0.05 tested by Student’s t-test vs non-PD TA cells.  
 
Figure 4: Expression of ADORA1 in cells derived from non-PD TA tissue and PD plaque tissue. (A) 
ADORA1 mRNA levels and (B) ADORA1 protein levels. Fibroblasts were treated with TGF-β1 at 10 ng/ml 
for 72 hours. Data points were plotted as mean ± SEM, N=3. Legend: * indicates P<0.05 tested by 
Student’s t-test vs untreated cells.  
 
Figure 5: Expression of ADORA2B in cells derived from non-PD TA tissue and PD plaque tissue. (A) 
ADORA2B mRNA levels and (B) ADORA2B protein levels. Fibroblasts were treated with TGF-β1 at 10 
ng/ml for 72 hours. Data points were plotted as mean ± SEM, N=3. Legend: * indicates P<0.05 tested by 
Student’s t-test vs untreated cells and # indicates P<0.05 tested by Student’s t-test vs non-PD TA cells. 
  
Figure 6: Effect of adenosine receptor ligands on TGF-β1-induced myofibroblast transformation. (A) 
Effect of CPA (ADORA1 agonist), (B) BAY 60-6583 (ADORA2B agonist), (C) SLV 320 (ADORA1 
antagonist) and (D) MRS 1754 (ADORA2B antagonist) on TGF-β1-induced myofibroblast transformation 
and cell viability. Cells derived from non-PD TA tissue and PD plaque tissue were exposed to a range of 
concentrations of the ligands between 0.03 and 100 μM and applied in co-incubation with TGF-β1 for 72 
hours. Data points were plotted as average ± SEM of the percentage of maximum response of either the 
α-SMA/DNA staining ratio (measure of myofibroblast transformation) or DNA staining (measure of cell 
numbers and viability), N=3. (E) Representative images of individual wells in an ICE plate obtained from 
Odyssey infrared imager in the presence of TGF-β1 and increasing concentrations of BAY 60-6583.  
 
Supplementary Figure 1: Effect of ADORA2B agonist, BAY 60-6583 on unstimulated fibroblasts. 
Cells derived from non-PD TA tissue and PD plaque tissue were exposed BAY 60-6583 (0.03 - 100 μM) for 
72 hours. Data points were plotted as average ± SEM of the percentage of maximum response of either 
the α-SMA/DNA staining ratio (measure of myofibroblast transformation) or DNA staining (measure of cell 
numbers and viability), N=3. Please note that no α-SMA was observed since these cells were not exposed 
to TGF-β1. 
 












